ライフサイエンスコーパス: renal replacement therapy

1 sfusion), and treatment (early initiation of renal replacement therapy).

2 s small (18 of 3369 [0.5%] patients received renal replacement therapy).

3 us system, or death), and interventions (ie, renal replacement therapy).

4 the baseline value or a new requirement for renal replacement therapy).

5 ressive renal insufficiency, or the need for renal-replacement therapy).

6 death, stroke, myocardial infarction, or new renal-replacement therapy).

7 d the rate of acute kidney injury and use of renal replacement therapy.

8 y composite outcome of hospital mortality or renal replacement therapy.

9 rate and end stage kidney disease requiring renal replacement therapy.

10 ent of renal function and discontinuation of renal replacement therapy.

11 w rate influences circuit life in continuous renal replacement therapy.

12 atinine was >1.2mg/dL or they were receiving renal replacement therapy.

13 herapy, including mechanical ventilation and renal replacement therapy.

14 iffer according to age at diagnosis or first renal replacement therapy.

15 ild renal insufficiency that did not require renal replacement therapy.

16 eft ventricular mechanical assist device, or renal replacement therapy.

17 sults primarily from an absence of access to renal replacement therapy.

18 The primary end point was the rate of renal replacement therapy.

19 ess than 10 mL/min/1.73 m2, or initiation of renal replacement therapy.

20 comycin in critically ill patients receiving renal replacement therapy.

21 increase greater than 0.5 mg/dL, or need for renal replacement therapy.

22 e for the likelihood of receiving continuous renal replacement therapy.

23 in adults and children who are not receiving renal replacement therapy.

24 acute renal failure and 78 (73.6%) required renal replacement therapy.

25 ng from mechanical ventilation, and need for renal replacement therapy.

26 , thereby postponing/preventing the need for renal replacement therapy.

27 al citrate anticoagulation during continuous renal replacement therapy.

28 trials of critically ill patients receiving renal replacement therapy.

29 ving donor transplantation within 3 years of renal replacement therapy.

30 d balance, however, was attenuated by use of renal replacement therapy.

31 t-effective and clinically effective form of renal replacement therapy.

32 age kidney disease criteria and new need for renal replacement therapy.

33 ction rates, length of stay, or the need for renal replacement therapy.

34 s and then compared with forms of continuous renal replacement therapy.

35 PKD2 and accounts for 10% of all patients on renal replacement therapy.

36 rates of 250 or 150 mL/min during continuous renal replacement therapy.

37 Continuous renal replacement therapy.

38 Critically ill adults requiring continuous renal replacement therapy.

39 ve and was treated with repeated sessions of renal replacement therapy.

40 end-stage kidney disease (ESKD) and need for renal replacement therapy.

41 e develop end-stage renal disease, requiring renal replacement therapy.

42 tilation hours of 130 and one third required renal replacement therapy.

43 increased use of mechanical ventilation and renal-replacement therapy.

44 t option for HIV-infected patients requiring renal-replacement therapy.

45 nly 57% of the control subjects had received renal-replacement therapy.

46 kidney injury and failure and treatment with renal-replacement therapy.

47 ved resuscitation with HES were treated with renal-replacement therapy.

48 to either an early or a delayed strategy of renal-replacement therapy.

49 n the delayed-strategy group did not receive renal-replacement therapy.

50 and a delayed strategy for the initiation of renal-replacement therapy.

51 ally ill on mechanical ventilation (41%) and renal replacement therapies (19%); 38% had received osel

52 ions may use hemodialysis (1D) or continuous renal replacement therapy (1D).

53 /24 hr, vasoactive or inotropic support, and renal replacement therapy); 2) 2006-2009, all mechanical

54 cal ventilation; 5 (19%) received continuous renal-replacement therapy; 22 (81%) received empirical a

55 Of the children managed with continuous renal replacement therapy, 26 (58%) survived: 19 were su

56 47%, P = 0.026) and receiving pretransplant renal replacement therapy (34% vs 12%, P < 0.001), and h

57 lacement therapy compared with those without renal replacement therapy (47.3% vs 71.8%; p < 0.001) ov

58 sor support (79.4% vs 55.0%; p < 0.001), and renal replacement therapy (48.8% vs 22.1%; p < 0.001).

59 1), vasopressors (23.2% vs 10.9%; P < .001), renal replacement therapy (49.6% vs 30.3%; P < .001), an

60 s 43 yr, p < 0.001) and more likely to be on renal replacement therapy (52% vs 38%, p = 0.003).

61 ts at ICU discharge, and no patient required renal replacement therapy 6 months after ICU admission.

62 echanical support (27% vs 0%, P < 0.01), and renal replacement therapy (61% vs 26%, P < 0.01).

63 ing remote ischemic preconditioning received renal replacement therapy (7 [5.8%] vs 19 [15.8%]; absol

64 stigate (a) the extent to which age at first renal replacement therapy, achievement of developmental

65 % CI, 0.44% to 10.47%), and increased use of renal replacement therapy among 9258 patients (RR, 1.32;

66 -year cumulative incidence rates were 3% for renal replacement therapy and 10% for death.

67 Primary outcomes for the present study were renal replacement therapy and death.

68 ted between effluent flow rate in continuous renal replacement therapy and extracorporeal clearance f

69 tus at hospital discharge, examined rates of renal replacement therapy and fluid overload, and measur

70 h high incidence of subsequent transition to renal replacement therapy and high in-hospital mortality

71 of synthetic colloids carries a high risk of renal replacement therapy and is not more effective than

72 ould be combined with research into low-cost renal replacement therapy and optimum clinical care, whi

73 end-stage chronic kidney disease or required renal-replacement therapy and was further increased with

74 ion, 30% required vasopressors, 17% required renal replacement therapy, and 28% had liver impairment

75 tly greater need for mechanical ventilation, renal replacement therapy, and ICU stay in patients in t

76 d Chronic Health Evaluation II score, use of renal replacement therapy, and infection by nonfermentin

77 uring acute kidney injury, even with ongoing renal replacement therapy, and is sufficient to cause ac

78 Only 10 (11%) could provide renal replacement therapy, and only 18 (20%) provided an

79 disease, diabetes, creatinine, total time on renal replacement therapy, and smoking.

80 5 treatment courses (17.8%), did not require renal replacement therapy, and subsided within 10 days f

81 en discussed with them before they initiated renal replacement therapy, and survey responses were lin

82 Patients receiving regional continuous renal replacement therapy anticoagulation with heparin a

83 th at day 90 and were more likely to require renal-replacement therapy, as compared with those receiv

84 raft futility (RAF-patient death or need for renal replacement therapy at 3 months) after simultaneou

85 ice was inserted preoperatively, or need for renal replacement therapy at any time postoperatively.

86 in/1.73 m2 or higher and who did not require renal replacement therapy at baseline.

87 infarction, repeat revascularization, or new renal-replacement therapy at 30 days and at 12 months af

88 ronic kidney disease and 901 (0.7%) required renal-replacement therapy at the time of inclusion.

89 Once renal replacement therapy became available, it became ap

90 type 3 who developed AKI requiring prolonged renal replacement therapy because of severe renal inflam

91 Prolonged renal replacement therapy before kidney transplant incre

92 failure requiring mechanical ventilation and renal replacement therapy, both patients recovered witho

93 splantation is considered the best available renal replacement therapy, but no guidelines exist to di

94 ransplantation is now an established form of renal replacement therapy, but the efficacy and safety o

95 Continuous renal replacement therapy can be used successfully in cr

96 /angiotensin II receptor blockers, lactates, renal replacement therapy, chronic heart disease, and in

97 calcium anticoagulation prolongs continuous renal replacement therapy circuit life compared with reg

98 ubjects who were treated with 857 continuous renal replacement therapy circuits (median 2 circuits pe

99 Based on four groups of continuous renal replacement therapy commencement ([group 1; refere

100 n RIFLE-I acute kidney injury and continuous renal replacement therapy commencement was 17.6 hours (i

101 lacement Therapy Study (proxy for continuous renal replacement therapy commencement) was the variable

102 as significantly lower in patients requiring renal replacement therapy compared with those without re

103 e unit, including prolonging the duration of renal replacement therapy, compared with withholding par

104 Continuous renal replacement therapy (CRRT) benefits patients with

105 Continuous renal replacement therapy (CRRT) is the most common dial

106 Continuous renal replacement therapy (CRRT) machines are used off l

107 AKI duration (P = 0.59) and rates of renal replacement therapy did not differ between study a

108 The degree of fluid overload at continuous renal replacement therapy discontinuation is also associ

109 , the change in fluid overload at continuous renal replacement therapy discontinuation was not signif

110 Median fluid overload at continuous renal replacement therapy discontinuation was significan

111 o recover sufficient renal function allowing renal replacement therapy discontinuation when baseline

112 However, standard renal replacement therapy does not correct this defect i

113 Secondary end points included use of renal replacement therapy, duration of intensive care un

114 hirty-one patients (50.0%) were treated with renal replacement therapy during extracorporeal membrane

115 However, the necessity of renal replacement therapy during extracorporeal membrane

116 ection, vasoactive agent use, and receipt of renal replacement therapy during ICU stay.

117 The need for renal replacement therapy (five [3.2%] and six [3.9%] pa

118 and dialysis dependency after initiation of renal replacement therapy for acute kidney injury.

119 ts to indicate the earlier use of continuous renal replacement therapy for both renal dysfunction and

120 support and patients initiated on continuous renal replacement therapy for indications other than acu

121 Children who received continuous renal replacement therapy for management of acute kidney

122 oneal dialysis (PD) is a life-saving form of renal replacement therapy for those with end-stage kidne

123 The role of renal replacement therapy for volume management is not w

124 dent association between RBC transfusion and renal replacement therapy-free days, mechanical ventilat

125 Time to initiate continuous renal replacement therapy from PICU admission was lower

126 y Score II, invasive mechanical ventilation, renal replacement therapy, fungal infections, and unknow

127 the composite primary end point of death or renal-replacement therapy had occurred in 158 of the 344

128 The term 'renal replacement therapy' has been employed for describ

129 38 to 1.59; P<0.001), as did those requiring renal-replacement therapy (hazard ratio, 1.83; 95% CI, 1

130 mission post kidney transplantation, chronic renal replacement therapy (hemodialysis or peritoneal di

131 ve and free of ventilation, vasopressors and renal replacement therapy in 28-day and 1-year survivors

132 eiving continuous mechanical ventilation and renal replacement therapy in a long-term care hospital w

133 mptoms, requiring mechanical ventilation and renal replacement therapy in a substantial proportion of

134 ttent hemodialysis, initiation of continuous renal replacement therapy in critically ill adults with

135 quently necessitate initiation of continuous renal replacement therapy in critically ill patients adm

136 ive drugs were used in 23 patients (68%) and renal replacement therapy in eight patients (24%).

137 06 adult African-American patients receiving renal replacement therapy in four dialysis units.

138 The guidelines for continuous renal replacement therapy in pediatric acute liver failu

139 e and free of ventilation, vasopressors, and renal replacement therapy in septic shock in 28-day surv

140 core stratification confirmed greater use of renal replacement therapy in the hydroxyethyl starch and

141 a substantial subgroup of patients requiring renal replacement therapy in the ICU.

142 There was less use of renal replacement therapy in the vasopressin group than

143 a role for earlier initiation of continuous renal replacement therapy in this population, and warran

144 A delayed strategy averted the need for renal-replacement therapy in an appreciable number of pa

145 The timing of renal-replacement therapy in critically ill patients who

146 equired in critically ill patients receiving renal replacement therapy, in the presence of high efflu

147 ciation between fluid overload at continuous renal replacement therapy initiation and mortality in pe

148 of illness, and fluid overload at continuous renal replacement therapy initiation found that fluid ov

149 e hundred thirty adult patients who required renal replacement therapy initiation in the ICU.

150 atric patients, fluid overload at continuous renal replacement therapy initiation is associated with

151 Median fluid overload at continuous renal replacement therapy initiation was significantly l

152 tion found that fluid overload at continuous renal replacement therapy initiation was the most consis

153 ing for percent fluid overload at continuous renal replacement therapy initiation, age, and severity

154 ciation between fluid overload at continuous renal replacement therapy initiation, fluid removal duri

155 Fluid overload, indication for continuous renal replacement therapy initiation, severity of illnes

156 had respiratory and hemodynamic supports at renal replacement therapy initiation, similarly distribu

157 ime of occurrence of acute kidney injury and renal replacement therapy initiation.

158 lly as time from ICU admission to continuous renal replacement therapy initiation.

159 those who survived to at least 90 days after renal replacement therapy initiation.

160 ildren who may benefit from early continuous renal replacement therapy initiation.

161 eplacement therapy (positive fluid balance x renal replacement therapy interaction (adjusted hazard r

162 he patients received mechanical ventilation, renal replacement therapy, invasive monitoring, vasopres

163 Mortality of patients on renal replacement therapy is affected by a combination o

164 use as supportive therapy even when complete renal replacement therapy is not indicated.

165 Continuous renal replacement therapy is valuable for surgical patie

166 Assessment scores and in patients receiving renal replacement therapies; it was less frequent in mal

167 y-nine patients aged 18 to 69 years starting renal replacement therapy (January 1, 1997 to December 3

168 12,282 patients aged 18 to 69 years starting renal replacement therapy (January 1, 1997, to December

169 e to initiate early and high-dose continuous renal replacement therapy led to increased survival with

170 n glomerular filtration rate (GFR), need for renal replacement therapy, length of stay, and overall s

171 is preferred initially (1D), but continuous renal replacement therapies may be considered if hemodia

172 Renal replacement therapy may be necessary in this chron

173 reater hemodynamic stability; yet continuous renal replacement therapy may not enhance patient surviv

174 tional intermittent hemodialysis, continuous renal replacement therapy may promote kidney recovery by

175 mortality; and days alive and not receiving renal replacement therapy, mechanical ventilation, or va

176 to evaluate the relationship between initial renal replacement therapy modality and the primary outco

177 ents with acute kidney injury, the impact of renal replacement therapy modality on long-term kidney f

178 Renal replacement therapy modified the association betwe

179 Rates of renal replacement therapy, mortality, and serious advers

180 ng of creatinine or the requirement of acute renal replacement therapy (n=58, 5.1%).

181 Of patients receiving renal replacement therapy, neither positive (adjusted od

182 rea, might explain the prolonged duration of renal replacement therapy observed with early parenteral

183 ians who are younger than 35 years used more renal replacement therapy (odds ratio, 1.04; 95% CI, 1-1

184 tion (odds ratio, 7.24; 95% CI, 2.24-23.40), renal replacement therapy (odds ratio, 6.12; 95% CI, 2.2

185 Data illustrate disparities in access to renal replacement therapy of any kind and in the use of

186 Peritoneal dialysis is the renal replacement therapy of choice for acute kidney inj

187 effect of timing of initiation of continuous renal replacement therapy on ICU mortality in children r

188 and low cardiac output syndrome but not for renal replacement therapy or deep sternal wound infectio

189 s type, length, site, and mode of continuous renal replacement therapy or international normalized ra

190 t least 40 hours apart, on treatment without renal replacement therapy or liver transplantation) or S

191 ed with placebo, did not reduce the need for renal replacement therapy or risk of 30-day mortality bu

192 p) at the end of DC insertion and after each renal-replacement therapy or plasma exchange session.

193 d duration greater than 48 hours, to perform renal-replacement therapy or plasma exchange, were rando

194 osis was associated with a decreased risk of renal replacement therapy (OR, 0.26 [95% CI, 0.11-0.60])

195 HUS (OR, 2.38 [95% CI, 1.30-4.35]; I2 = 2%), renal replacement therapy (OR, 1.90 [95% CI, 1.25-2.90];

196 persisted for at least 1 month, the start of renal replacement therapy, or an eGFR less than 10 mL/mi

197 oactive medication administration, delirium, renal replacement therapy, or body mass index >/= 30 kg/

198 ion in estimated glomerular filtration rate, renal replacement therapy, or renal death).

199 ted glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (h

200 of the serum creatinine level, initiation of renal-replacement therapy, or death from renal disease)

201 1) needed vasopressor treatment (P < 0.05), renal replacement therapy (P < 0.05), and mechanical ven

202 18%) allocated to the placebo group received renal replacement therapy (P = .47).

203 p < 0.0001, p < 0.0001, and p = 0.0004), and renal replacement therapy (p = 0.0008, p = 0.0008, and p

204 d from 91.2% to 78.4% for those who received renal replacement therapy (p = 0.04).

205 udy site (P = 0.041), and BG positivity with renal replacement therapy (P = 0.05) and study site (P =

206 ARAS was not associated with need for renal replacement therapy (p = 0.4), longer length of st

207 s a smaller proportion of patients receiving renal-replacement therapy (P=0.04) and a shorter duratio

208 the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infa

209 Even after 4 days of renal replacement therapy, plasma from patients with sep

210 Renal-replacement therapy poses several practical and et

211 , which was attenuated in those who received renal replacement therapy (positive fluid balance x rena

212 nths after transplant), a longer duration of renal replacement therapy pretransplant and the occurren

213 nal replacement therapy versus patients with renal replacement therapy prior to extracorporeal membra

214 sion analysis suggests that the necessity of renal replacement therapy prior to extracorporeal membra

215 development of acute kidney injury requiring renal replacement therapy prior to extracorporeal membra

216 criteria and 45 of these received continuous renal replacement therapy prior to transplantation or re

217 tions (mechanical ventilation, vasopressors, renal replacement therapy) provided in the ICU and outco

218 We identified 2,315 continuous renal replacement therapy recipients of whom 2,004 (87%)

219 Continuous renal replacement therapy recipients were matched 1:1 to

220 k for associated outcomes including need for renal replacement therapy, rehospitalization, and death,

221 py Study, earlier commencement of continuous renal replacement therapy relative to RIFLE-I acute kidn

222 had pre-existing ESRD and CKD not requiring renal replacement therapy, respectively.

223 s on-pump) and in-hospital death or incident renal replacement therapy (RRT) across strata of preoper

224 29.93; 95% CI, 1.51-592.57, P=0.03), whereas renal replacement therapy (RRT) and Aspergillus coloniza

225 plifies the difficulties faced in supporting Renal Replacement Therapy (RRT) and providing equitable

226 evalence of the disease and worldwide use of renal replacement therapy (RRT) are expected to rise sha

227 Study endpoints were renal replacement therapy (RRT) at 1 month and the need

228 start dialysis, defined as the initiation of renal replacement therapy (RRT) at an estimated GFR >/=1

229 tions, patients with ESRD who do not receive renal replacement therapy (RRT) develop signs and sympto

230 Optimal timing of initiation of renal replacement therapy (RRT) for severe acute kidney

231 Renal failure requiring renal replacement therapy (RRT) has detrimental effects

232 ve years (2004-2011) from all those starting renal replacement therapy (RRT) in this population.

233 We evaluated the effect of renal replacement therapy (RRT) on serum ammonia level a

234 Even with aggressive medical care and renal replacement therapy (RRT) the morbidity, mortality

235 Patients with established AKI requiring renal replacement therapy (RRT) were excluded.

236 eatinine clearance 0-236mL/min; 29 receiving renal replacement therapy (RRT)) were subjected to popul

237 eatinine clearance 0-236mL/min; 29 receiving renal replacement therapy (RRT)) were subjected to popul

238 od pressure (BP), decreased kidney function, renal replacement therapy (RRT), and death.

239 hoc analysis outcomes included the need for renal replacement therapy (RRT), length of stay in ICU a

240 4%) stage III, and 25 patients (5%) required renal replacement therapy (RRT).

241 vents were renal (incident renal failure and renal replacement therapy [RRT]) and bone events (incide

242 age CKD and end-stage CKD (e.g., patients on renal replacement therapy [RRT]) was estimated using Cox

243 ative extracorporeal membrane oxygenation or renal replacement therapy, severe preimplant tricuspid r

244 Policy changes to improve access to renal replacement therapy should be combined with resear

245 Continuous renal replacement therapy should be considered at an ear

246 The terminology of 'renal replacement therapy' should be supplanted by more

247 eceive a liver transplant, use of continuous renal replacement therapy significantly improved surviva

248 emia by 48 hours after initiating continuous renal replacement therapy significantly improved surviva

249 Physiology Score II, mechanical ventilation, renal replacement therapy, spontaneous bacterial periton

250 and 35.6 mL/min, respectively, in continuous renal replacement therapy studies.

251 o end-stage kidney disease (ESKD), requiring renal replacement therapy, such as dialysis.

252 those in the high-target group required less renal-replacement therapy than did those in the low-targ

253 initiation, fluid removal during continuous renal replacement therapy, the kinetics of fluid removal

254 Despite advances in renal replacement therapy, the mortality rate for acute

255 ined to be similar or higher than continuous renal replacement therapy therapies.

256 on the basis of the intensity of continuous renal replacement therapy; this effect may have been obs

257 component composite of death through day 30, renal-replacement therapy through day 30, perioperative

258 th of stay, ventilator usage, and continuous renal replacement therapy usage compared with other serv

259 Continuous renal replacement therapy usage, defined as percent of p

260 Continuous renal replacement therapy using blood flow rate set at 2

261 Initial receipt of continuous renal replacement therapy versus intermittent hemodialys

262 g patients who initially received continuous renal replacement therapy versus intermittent hemodialys

263 differed significantly for patients without renal replacement therapy versus patients with renal rep

264 ) assigned to HES 130/0.42 were treated with renal-replacement therapy versus 65 patients (16%) assig

265 bjective was to determine whether continuous renal replacement therapy was associated with a lower ri

266 Earlier initiation of continuous renal replacement therapy was associated with lower mort

267 Risk of renal replacement therapy was greater after hydroxyethyl

268 Renal replacement therapy was more common during periods

269 46.0 hr), earlier commencement of continuous renal replacement therapy was not associated with a sign

270 Time from diagnosis of AAN to renal replacement therapy was relatively short (1 [0-15]

271 Renal replacement therapy was required in 64 of 90 (71%)

272 Acute renal failure requiring renal replacement therapy was the third most common comp

273 Renal replacement therapy was used before operation in 9

274 Renal replacement therapy was used in 156 (11.0%) in col

275 in serum creatinine or a new requirement for renal replacement therapy was within the protocol-define

276 2 to 0.98; P=0.03), and the relative risk of renal-replacement therapy was 0.71 (95% CI, 0.49 to 1.03

277 With the delayed strategy, renal-replacement therapy was initiated if at least one

278 Renal-replacement therapy was initiated in 13 of 4687 pa

279 of death or severe renal failure leading to renal-replacement therapy was lower among those who init

280 With the early strategy, renal-replacement therapy was started immediately after

281 Renal-replacement therapy was used in 235 of 3352 patien

282 onic kidney disease (i.e., disease requiring renal-replacement therapy) was estimated with the use of

283 critically ill patients receiving continuous renal replacement therapy, we aimed to assess the variab

284 acute kidney injury treated with continuous renal replacement therapy, we found no association of RB

285 echanical ventilation, vasoactive drugs, and renal replacement therapy were administered to 25 (18%),

286 from mechanical ventilation and the need for renal replacement therapy were also comparable in seropo

287 ta on 464,547 individuals who were beginning renal replacement therapy were analyzed.

288 amples of patients with kidney failure or on renal replacement therapy were excluded.

289 e and free of ventilation, vasopressors, and renal replacement therapy were highly significantly asso

290 Invasive positive pressure ventilation and renal replacement therapy were used in only 34.6% and 11

291 These patients will frequently require renal replacement therapy when presenting for hepatic tr

292 critically ill patients receiving continuous renal replacement therapy, which did not only appear to

293 ge pediatric population receiving continuous renal replacement therapy while on extracorporeal membra

294 l disease in the United States without prior renal replacement therapy who had incident vascular acce

295 ributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplant

296 of death or severe renal failure leading to renal-replacement therapy within 30 days after randomiza

297 infarction, repeat revascularization, or new renal-replacement therapy within 30 days and within 12 m

298 50% above first value or initiation of acute renal-replacement therapy, within the first 5 days of ho

299 Continuous renal replacement therapy without anticoagulation was mo

300 se and accounts for 7-10% of all patients on renal replacement therapy worldwide.